Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

<< Previous
Bullboard Posts
Next >>
Post by quinlashon Jul 29, 2020 8:42am
192 Views
Post# 31335680

Article: Aphria Target - Raised to $11 CDN

Article: Aphria Target - Raised to $11 CDN
Bashers want your shares for cheap or the price to fall, live with it, it's what happens in forums everyday. 

Do your own research.


Cantor Fitzgerald analyst Pablo Zuanic reiterated his Overweight rating for Aphria and raised his price target from CA$10.50 (US$7.84) to CA$11 (US$8.21).

Aphria continues to be Zuanic's top stock pick among Canadian cannabis producers. He said the company is gaining recreational market share in Canada and will likely beat consensus fourth-quarter sales estimates by roughly $2.24 million.
 
Zuanic is also projecting 25% sequential recreational cannabis sales growth compared to just 20% sequential sales growth for the overall recreational market.
 
“We think LPs like APHA, with positive EBITDA, consistent domestic rec/med market share gains, and which are sensibly building businesses overseas (MJ reg issues notwithstanding, we should remember 95% of the world’s population lives outside NA, and we still think MJ deregulation will be a global phenomenon), will outperform,” Zuanic wrote on Monday.
 
Unfortunately, Aphria investors should keep their expectations muted when it comes to profitability in the fourth quarter, Zuanic added. He said COVID-19 operating disruptions during the quarter likely weighed on cannabis EBITDA margins.
 
In addition, Zuanic is calling for cash burn to improve sequentially from C$91 million in the third quarter to just C$34 million in the fourth quarter. Zuanic is also projecting net cash of C$128 million.
 
In the longer-term Zuanic says Aphria should benefit from the Canadian cannabis market expanding from $1.6 billion in 2019 to $6.2 billion by 2024. Cantor is also projecting the US cannabis market will grow from $12 billion in 2019 to $31 billion by 2024.


Link to Full Article:

https://finance.yahoo.com/news/cantor-fitzgerald-raises-aphria-target-162151891.html#:~:text=Cantor%20Fitzgerald%20analyst%20Pablo%20Zuanic,CA%2411%20(US%248.21).&text=Aphria%20continues%20to%20be%20Zuanic's%20top%20stock%20pick%20among%20Canadian%20cannabis%20producers.&text=Zuanic%20is%20also%20projecting%20net%20cash%20of%20C%24128%20million.
<< Previous
Bullboard Posts
Next >>